Background: Chronic obstructive lung disease (COPD) is the 3rd leading cause of death in the world. Many studies searching for a potential new treatment. Revefenacin is a new M3 muscarinic receptor antagonist, causing bronchodilatation and relieve COPD symptoms. We conducted this analysis to know the efficacy of revefenacin nebulization in COPD patients, and increase the understanding of this subtype of drugs to other physicians. Methods: Literature search was conducted using Pubmed database until August 2019 to find randomized controlled trial (RCTs), which assessed revefenacin nebulization effects on FEV1 in COPD patients with 2 different dose (88 mcg and 175 mcg) . We also added relevant complete clinical trial later. Treatment effects were considered as Mean and corresponding standard deviation (SD) in FEV1 changes from the baseline. We performed data analysis using RevMan. We used random-effects model and sub-group analysis to estimate the overall summary effect of this study in each dose group. Results: A total of 4 trials (1152 participants) were included in the meta-analysis. The results suggested that revefenacin has significant effect on increasing FEV1 changes from the baseline in both 88 mcg (121.99 mL; 95% CI: 69.00 to 174.99; p = <0.00001) and 175 mcg doses (141.23 mL; 95% CI: 115.24 to 167.21; p = <0.00001). There are no significant difference between the 2 group of doses (p= 0.52). Conclusions: Revefenacin nebulization improved FEV1 in COPD patients in both two doses. Patients nebulized with either 88 mcg and 175 mcg of revefenacin shown no significant difference. However, further studies with larger scale and better designs are needed to confirm the results and eliminate the bias.